Athersys says it is working as fast as it can to launch a pivotal trial of its MultiStem® adult-derived "off-the-shelf" stem cell product in acute respiratory distress syndrome (ARDS), after the clinical program received the “Highly Relevant” designation for COVID-19 from BARDA. [Athersys . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge